232 related articles for article (PubMed ID: 16870508)
21. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases.
Martins I; Deshayes F; Baton F; Forget A; Ciechomska I; Sylla K; Aoudjit F; Charron D; Al-Daccak R; Alcaide-Loridan C
Eur J Immunol; 2007 Mar; 37(3):788-97. PubMed ID: 17304627
[TBL] [Abstract][Full Text] [Related]
22. Prolonged MHC class II expression and CIITA transcription in human keratinocytes.
Takagi A; Nishiyama C; Kanada S; Niwa Y; Fukuyama K; Ikeda S; Okumura K; Ogawa H
Biochem Biophys Res Commun; 2006 Aug; 347(2):388-93. PubMed ID: 16836979
[TBL] [Abstract][Full Text] [Related]
23. Hexim1 sequesters positive transcription elongation factor b from the class II transactivator on MHC class II promoters.
Kohoutek J; Blazek D; Peterlin BM
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17349-54. PubMed ID: 17088550
[TBL] [Abstract][Full Text] [Related]
24. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
25. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.
De Lerma Barbaro A; Procopio FA; Mortara L; Tosi G; Accolla RS
Eur J Immunol; 2005 Feb; 35(2):603-11. PubMed ID: 15627980
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
Vaissière T; Sawan C; Herceg Z
Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells.
Liu JH; Bian YM; Xie Y; Lu DP
Mol Med Rep; 2015 Jul; 12(1):1059-65. PubMed ID: 25815463
[TBL] [Abstract][Full Text] [Related]
28. Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA).
Patarroyo JC; Stuve O; Piskurich JF; Hauser SL; Oksenberg JR; Zamvil SS
Genes Immun; 2002 Feb; 3(1):34-7. PubMed ID: 11857059
[TBL] [Abstract][Full Text] [Related]
29. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
30. Polymorphism in MHC class II transactivator gene is not associated with susceptibility to colorectal cancer in Swedish patients.
Mumtaz M; Löfgren S; Hugander A; Dimberg J
Anticancer Res; 2008; 28(3B):1789-91. PubMed ID: 18630461
[TBL] [Abstract][Full Text] [Related]
31. Early epigenetic events regulate the adaptive immune response gene CIITA.
Mehta NT; Truax AD; Boyd NH; Greer SF
Epigenetics; 2011 Apr; 6(4):516-25. PubMed ID: 21266852
[TBL] [Abstract][Full Text] [Related]
32. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells.
Le E; Zhang H; Blanck G
Anticancer Res; 2005; 25(6B):3889-92. PubMed ID: 16312044
[TBL] [Abstract][Full Text] [Related]
33. Transcription-coupled deposition of histone modifications during MHC class II gene activation.
Rybtsova N; Leimgruber E; Seguin-Estévez Q; Dunand-Sauthier I; Krawczyk M; Reith W
Nucleic Acids Res; 2007; 35(10):3431-41. PubMed ID: 17478518
[TBL] [Abstract][Full Text] [Related]
34. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic regulation during B cell differentiation controls CIITA promoter accessibility.
Green MR; Yoon H; Boss JM
J Immunol; 2006 Sep; 177(6):3865-73. PubMed ID: 16951349
[TBL] [Abstract][Full Text] [Related]
36. Genetic and epigenetic control of the major histocompatibility complex class Ib gene HLA-G in trophoblast cell lines.
Holling TM; Bergevoet MW; Wierda RJ; van Eggermond MC; van den Elsen PJ
Ann N Y Acad Sci; 2009 Sep; 1173():538-44. PubMed ID: 19758196
[TBL] [Abstract][Full Text] [Related]
37. Function and regulation of class II transactivator in the immune system.
Chang CH; Gourley TS; Sisk TJ
Immunol Res; 2002; 25(2):131-42. PubMed ID: 11999167
[TBL] [Abstract][Full Text] [Related]
38. [Construction of mutants of MHC class II molecule transactivator gene capable of suppressing HLA-DR/DQ expression and exploration on their mechanism].
Ou QS; Lin L; Huang LD; Lu PH; Zhou GY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Sep; 19(5):417-20. PubMed ID: 15169643
[TBL] [Abstract][Full Text] [Related]
39. Differential nerve injury-induced expression of MHC class II in the mouse correlates to genetic variability in the type I promoter of C2ta.
Harnesk K; Swanberg M; Diez M; Olsson T; Piehl F; Lidman O
J Neuroimmunol; 2009 Jul; 212(1-2):44-52. PubMed ID: 19481818
[TBL] [Abstract][Full Text] [Related]
40. [Specific promoter activity of CIITA-pI in dendritic cells].
Zhang Y; Shen Q
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jan; 20(1):55-7. PubMed ID: 15182622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
